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a  b  s  t  r  a  c  t
Artesunate  is a potent  and  rapidly  acting  blood  schizontocide  used  to treat chloroquine
resistant  malaria.  Artesunate  has  been  reported  to cause  embryo,  reduced  reproductive
capacity,  hepatotoxicity,  neurotoxicity  and  hematological  abnormalities.  Previously  tox-
icity studies  on artesunate  have  been  done  in  2–10  mg/kg  dose  range  mostly  for  7 days,
scientiﬁc  studies  on  sub-chronic  exposure  of artesunate  is not  been  reported  so  for.  The
present  study  evaluates  sub-chronic  safety  proﬁle  of artesunate  on  45 days  oral  admin-
istration at  2,  4 and  8 mg/kg/day.  Authentication  of  artesunate  has  been  done  by  color
test,  pH,  melting  point,  loss  on drying,  UVmax, TLC  and  HPLC  study.  Artesunate  has  non-
signiﬁcant  effect  on  liver  and kidney  weight.  Serum  glutamate  oxaloacetate  transaminase
(SGOT),  serum  glutamate  pyruvate  transaminase  (SGPT),  serum  alkaline  phosphate  (ALP),
cholesterol  (TC),  triglyceride  (TG),  total  protein,  albumin,  bilirubin,  creatinine,  urea  and  glu-
cose content  were estimated  after  45 days  treatment  along  with  hematological  screening.
Artesunate  treatment  for 45  days  signiﬁcantly  increased  (p <  0.05–0.001)  SGOT,  SGPT, ALP,
TC, TG,  total  bilirubin,  glucose  level  at 8 mg/kg/day  dose.  It  has  non-signiﬁcant  effect  on
serum  total  protein,  albumin,  creatinine  and  urea.  Hemoglobin,  total  RBC,  platelet,  lym-
phocytes,  basophil,  mean  cell  volume  and  mean  corpuscular  hemoglobin  concentration
have  not  changed  but  total  WBC,  neutrophil,  eosinophil,  packed  cell  volume  and mean
cell  hemoglobin  were  increased  signiﬁcantly  (p <  0.01)  at 8 mg/kg/day  dose.  Artesunate
treatment  at  4 and  8 mg/kg/day  showed  sinusoidal  dilation,  cytoplasmic  vaculation,  focal
necrosis,  sinusoidal  congestion  and  extensive  inﬂammatory  changes,  whereas  kidney  was
free  of any deleterious  effect.
Conclusion:  Sub-chronic  exposure  of  artesunate  at 8 mg/kg/day  dose  for 45  days  period
cause  hepatic  damage  along  with  hematological  abnormalities  signifying  safety  concern.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
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1. Introduction
Artemisia annua commonly known as sweet wormwood
or sweet annie is a annual herb used in treatment of
malaria over 2000 years in China. The active ingredient
artemisinin was  isolated in 1972 and subsequently other
semi-synthetic antimalarial drugs were produced. The low
water solubility of artemisinin made it marginally effec-
tive against malaria. Derivatives like artemether, arteether,
artesunate, artenilic acid are effective anti-malarial against
is is an open access article under the CC BY-NC-ND license
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he asexual forms of the erythrocytic stage of Plasmodium
alciparum and Plasmodium vivax malaria [1]. Artesunate
s a semi-synthetic water soluble derivative of artemisinin
2]. Artesunate is always given with another antimalarial
uch as meﬂoquine [3] or amodiaquine [4] to avoid the
evelopment of resistance. The combination of artesunate
nd amodiaquine has been found to be equivalent to co-
rtemether [5].
Artesunate is used especially to treat chloroquine resis-
ant malaria. Artesunate is a potent and rapidly acting
lood schizontocide concentrated in parasitized erythro-
ytes but had no hypozoiticidal activity. Artesunate exerts
ts anti-malarial activity by generation of reactive oxygen
pecies (ROS) by iron-catalyzed cleavage of the endoperox-
de bridge through endoperoxide bond [6,7]. It is converted
o active metabolite dihydroartemesinin that binds tightly
o parasite infected erythrocyte membrane then inhibits
he sarcoplasmic/endoplasmic reticulum calcium ATPase
ncoded by P. falciparum [8–10]. Artesunate has demon-
trated the fastest clearance of all antimalarial currently
sed and acts primarily on the trophozite phase, thus pre-
enting progression of the malaria disease.
Literature citation showed that reported toxicity stud-
es on artesunate have been mostly done following 7 days
dministration in a dose range of 2–10 mg/kg/day (oral or
P). Artesunate has been reported to cause embryo lethality
nd malformations when administered orally to rats dur-
ng organogenesis [11,12]. Long term administration for 6
eeks at 2.9 mg/kg dose reduces reproductive efﬁciency of
ale rat and toxicity on development of fetus in female
ats [13]. Artesunate induced hepatotoxicity when given at
–8 mg/kg/day dose for 5–7 days along with adverse action
n kidney, biochemical parameters of serum and hemato-
ogical induces in rat [14,15]. Artesunate at 16 mg/kg/day
ose causes hepatotoxicity in guinea pig when adminis-
ered for 7 days [16]. Artesunate at 4–8 mg/kg/day dose
iven into 7 day had no effect on the histology of the heart
17]. The studies showed hepatotoxicity and hemolytic
ffects were clearly associated with artesunate [18]. The
herapeutic dose of artesunate in adult human is minimum
0–200 mg/day. Scientiﬁc studies on sub-chronic toxicity
n this dose range have not been reported so far.
Continued research is needed to establish safety and
fﬁcacy of the anti-malarial regimen of artesunate in
atients receiving the therapy. The present study aims at
valuation of complete safety proﬁle of artesunate consid-
ring effect on liver, kidney and blood parameters of rat
ollowing sub-chronic 45 days oral administration of arte-
unate in three graded dose that is 2, 4 and 8 mg/kg/day.
he dose 8 mg/kg/day is twice the recommended daily
ose, selected for this study to explore maximum possible
dverse effect of artesunate on long term dosing. The study
utcome will provide data regarding sub-chronic safety
roﬁle of artesunate.
. Materials and methods.1. Procurement of artesunate
Artesunate was obtained as gift sample from IPCA Phar-
aceutical Ltd., Ratlam, MP,  India.orts 2 (2015) 280–288 281
2.2. Authentication and standardization of artesunate
Identiﬁcation test: Artesunate 100 mg  was  dissolved
in 40 ml  of anhydrous ethanol, shaken and ﬁltered
through Whatman ﬁlter paper. Hydroxylamine hydrochlo-
ride 0.5 ml  and 8% NaOH 0.25 ml  was added and heated
to boiling followed by cooling. Few drops of dilute HCl
and then few drops 5% ferric chloride was  added to
observe color development [19].pH determination:  Arte-
sunate 10 mg  was dissolved 10 ml  of distilled water. pH of
this solution was measured with a digital pH meter (MS
Electronics India Pvt. Ltd., Panchkula, India) and recorded
[20].
Melting point determination:  A thin walled capillary was
closed at one end than sufﬁcient quantity of artesunate was
introduced in the capillary. The temperature of melting
point apparatus (Jyoti Scientiﬁc Industry, Gwalior, India)
was maintained initially at 100 ◦C, the capillary was placed
in apparatus and melting point was recorded [20].
Loss on drying:  The loss on drying test is designed to
measure the amount of water and volatile matters in a sam-
ple when the sample is dried under speciﬁed conditions.
The 500 mg  artesunate sample was weighted, heated in an
oven for appropriate period, cooled in the dry atmosphere
of a desiccator and then reweighted [20].
2.3. UV spectroscopy
A simple, rapid, precise and accurate UV–vis spec-
trophotometric method developed by Kalyankar et al. [21]
has been used for screening UVmax of artesunate. Accu-
rately weighed quantity of artesunate was  dissolved in
methanol to get the concentration of 50 mg/ml. Appro-
priate dilutions were prepared from the standard stock
solution and scanned in the spectrum range of 400–200 nm.
2.4. Thin layer chromatography (TLC)
On the basis of literature, TLC of artesunate was per-
formed on 10 cm × 10 cm precoated Merck silica gel 60 F254
plates using ethyl acetate:toluene (5:95) as a solvent sys-
tem [20]. Artesunate was dissolved in dehydrated ethanol
and ﬁltered through Whatman ﬁlter paper. The ﬁltrate was
evaporated, the residue dissolved in toluene (0.1 mg/ml)
and spotted. The developed plates were air-dried, sprayed
with anisaldehyde methanol solution and heated to 120 ◦C
for 5 min. The plates were visualized and Rf value calcu-
lated.
2.5. High performance liquid chromatography (HPLC)
Waters HPLC instrument (Alliance 510) with UV-484
Data Ace software (I.D.: AL-011) was  used for analysis.
Separation was carried out on Thermo C18 (250 × 4.6) col-
umn using acetonitrile and 25 mM potassium dihydrogen
phosphate buffer in ratio of 70:30 (v/v) ﬁltered through
0.2 m nylon membrane ﬁlter and degassed prior to use.
Mobile phase ﬂow rate was maintained at 1.0 ml/min in
a run time of 10 min. Sample solution of artesunate was
prepared in mobile phase, sonicated to dissolve and get
a working standard concentration of 100 g/ml. Samples
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Fig. 1. UV spectrum of artesunate sample in methanol at 50 g/ml concentration
reported in Kalyankar et al. [21].
Fig. 2. TLC of artesunate sample in solvent system ethyl acetate:toluene
(5:95) showed Rf at 0.43. screened at 220–240 nm showed UVmax 225 nm as compared to 240 nm
were injected using Rheodyne injector with 20 l loop and
detection was carried out at 220–240 nm [22].
2.6. Sub-chronic toxicity study
Experimental animals: Wistar albino rats of either sex
weighing between 150 and 200 g were obtained from the
animal house of the Radharaman College of Pharmacy,
Bhopal. The animals were allowed to free access of water
and standard palette diet (Hindustan Lever Ltd.). Animals
were housed in polycarbonate cages, paddy husk bed-
ding with a controlled ambient temperature (22 ± 2 ◦C),
humidity (60 ± 5%) and a 12 h light/dark cycle. All the
experimental procedures and protocols used in the study
were reviewed and approved by the Institutional Animal
Ethical Committee (Approval no. IAEC/RCP/Oct 2012/05).
Fig. 3. HPLC spectrum of artesunate sample in acetonitrile and 25 mM
potassium dihydrogen phosphate buffer (70:30, v/v) showed retention
time at 5.324 min  compared to 5.202 min reported by Gandhi et al. [22].
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Table  1
Effect of artesunate 45 days treatment on % change in body weight.
Treatment group (mg/kg/day, p.o.) On 7th day On 14th day On 21st day On 28th day On 35th day On 42nd day
Vehicle control 5.54 6.78 8.46 13.12 22.39 27.68
Artesunate (2) 5.60 6.25 
Artesunate (4) 4.25 5.95 
Artesunate (8) 4.46 3.90 
Table 2
Effect of artesunate 45 days treatment on relative weight of liver and
kidney.
Treatment group
(mg/kg/day, p.o)
Liver weight (g/100 g
body weight)
Liver weight (g/100 g
body weight)
Vehicle control 3.95 ± 0.83 0.89 ± 0.07
Artesunate (2) 3.46 ± 0.45ns 0.84 ± 0.03ns
Artesunate (4) 3.24 ± 0.73ns 0.86 ± 0.04ns
Artesunate (8) 2.94 ± 0.36ns 0.76 ± 0.02ns
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a = 6. All values were ns = not signiﬁcant when compared to vehicle control
roup.
Study protocol: Wistar rats were randomly divided into
 groups of 6 rats each. Group A animals were the vehicle
ontrol, treated with 0.9% sodium chloride in 2% carboxy
ethyl cellulose (CMC). Group B, C and D animals were
dministered with oral artesunate at 2, 4 and 8 mg/kg/day,
.o. in 2% CMC  continuously for 45 days.
Starting from the 1st day of the drug administration
ody weight was measured on each 7th day and percent
ncrease in body weight was calculated. After the exper-
mental period the animals were sacriﬁced 2 h after last
ose administration by cervical dislocation, the thoracic
egion was opened to expose the heart. Blood was  collected
y cardiac puncture in dry heparinised tubes and used
or estimation of hematological indices. Another aliquot
f blood was placed in plain centrifuge tubes allowed to
oagulate for 30 min  in room temperature and centrifuged
t 3000 rpm for 10 min. The supernatant serum was col-
ected and used for estimation of biochemical parameters.
mmediately following blood collection, the liver and kid-
ey were removed, washed in cold saline, pressed between
lter paper pads and carefully weighed using a digital
eighing balance. Relative organ weights for 100 g body
eight was calculated and recorded. The liver and kidney
issues were immediately preserved in 10% formalin for
istopathology.
Estimation of blood marker enzymes: Assay of serum glu-
amate oxaloacetate transaminase (SGOT) [23] and serum
lutamate pyruvate transaminase (SGPT) [23], cholesterol
TC) [24], triglyceride (TG) [25], bilirubin [26], creati-
ine [27], urea [28] and glucose [29] was done in Star
1 Plus, Autoanalyzer by using the commercially avail-
ble standard kit (ERBA Diagnostic Mannheim GmbH,
annheim, Germany). Total protein [30] content of serum
as estimated following modiﬁed biuret method using a
tandard kit of Span Diagnostics Ltd., Surat, India. Serum
lkaline phosphate (ALP) [31] and albumin [32] were esti-
ated using kit obtained from Lab-Care Diagnostic Pvt. Ltd.,
umbai, India.
Hematological parameters: Estimation of hemoglobin
Hb) content (Sahli’s hemoglobinometer), total WBC, RBC
nd platelet count (Neubauer hemocytometer; Feinoptik,6.70 8.41 15.42 18.35
6.72 7.70 9.52 11.65
4.25 5.78 8.32 10.22
Germany) was done using standard technique and dif-
ferential WBC  count (neutrophil, eosinophil, basophil,
lymphocyte and monocyte) was done by Leishman’s stain-
ing method. Packed cell volume (PCV) is the percentage of
RBC in the blood. PCV was  estimated centrifuging blood in
hematocrit tube and reading % RBC in a hematocrit reader
[33].
Mean cell volume (MCV) indicates the volume of the
average red cell in a sample expressed in femtoliters (ﬂ)
and calculated by using the formula: MCV  = PCV/RBC × 10.
Mean cell hemoglobin (MCH) represents the absolute
amount of hemoglobin in the average red cell in a sample in
units of picogram (pg) per cell. The MCH  is calculated from
the hemoglobin and the RBC using the following formula:
MCH  = (Hb × 10)/RBC.
Mean corpuscular hemoglobin concentration (MCHC)
is the average hemoglobin concentration in the red blood
cells. The MCHC expressed as the amount of hemoglobin
per deciliter of red cells (g/dl) and calculated as follows:
MCHC = Hb/PCV.
Histology of liver and kidney:  Parafﬁn sections of liver and
kidney were prepared, stained with hematoxylin and eosin
and processed for light microscope following the technique
of Nanji et al. [34].
2.7. Statistical analysis
All data are presented as mean ± SEM. Experimental
data was analyzed using one-way ANOVA followed by Stu-
dent’s t-test to compare the difference between the control
and treated values. p value < 0.05 was considered signiﬁ-
cant. Graph Pad Prism Version 3.02 was used for statistical
calculations.
3. Result
3.1. Authentication and standardization of artesunate
Emergence of light red violet color conﬁrmed presence
of artesunate as described in International Pharmacopoeia
[20]. The pH of artesunate was  obtained 5.38. The melting
point of artesunate was  obtained at 134.6 ◦C. The loss on
drying of artesunate was  obtained as 0.25%. UV spectrum of
artesunate in methanol at 50 g/ml concentration showed
UVmax at 225 nm as compared to reported 240 nm (Fig. 1)
in Kalyankar et al. [21]. In Fig. 2 artesunate showed Rf
value of 0.43 in solvent system ethyl acetate:toluene (5:95).
HPLC spectrum of artesunate in acetonitrile and 25 mM
potassium dihydrogen phosphate buffer (70:30) showed
at retention time 2.904 min  (Fig. 3).
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Table 3
Effect of artesunate 45 days treatment on biochemical parameter of rats.
Treatment group
(mg/kg/day, p.o)
SGOT (IU/L) SGPT (IU/L) ALP (IU/L) TC (mg/dl) TG (mg/dl) TP (g/dl) Albumin
(g/dl)
Total bilirubin
(mg/dl)
Creatinine
(mg/dl)
Urea (mg/dl) Glucose (g/dl)
Vehicle control 27.70 ± 2.20 14.91 ± 1.31 110.30 ± 4.03 175.78 ± 10.33 105.35 ± 7.36 7.70 ± 1.02 3.90 ± 0.65 0.99 ± 0.06 0.68 ± 0.02 4.35 ± 0.93 110.93 ± 5.63
Artesunate (2) 28.66 ± 2.49ns 26.62 ± 2.76a 213.15 ± 9.65c 255.64 ± 13.10b 168.17 ± 9.82b 8.15 ± 1.96ns 4.30 ± 0.96ns 1.76 ± 0.21ns 0.85 ± 0.01ns 4.49 ± 0.33ns 105.32 ± 4.96ns
Artesunate (4) 41.39 ± 2.78a 37.58 ± 2.86c 285.82 ± 8.66c 277.99 ± 12.75c 178.95 ± 10.05c 9.11 ± 1.14ns 2.77 ± 0.26ns 2.13 ± 0.42ns 1.08 ± 0.21ns 4.27 ± 0.67ns 125.75 ± 6.33ns
Artesunate (8) 62.64 ± 3.75c 51.62 ± 2.77c 362.31 ± 1.19c 285.18 ± 15.06c 245.36 ± 12.09c 9.27 ± 1.06ns 1.80 ± 0.63ns 3.73 ± 0.96a 1.14 ± 0.19ns 4.39 ± 0.85ns 144.97 ± 8.42b
n = 6. ns = not signiﬁcant when compared to vehicle control group, SGOT = serum glutamate oxaloacetate transminase, SGPT = serum glutamate pyruvate transminase, ALP = alkaline phosphate, TC = total cholesterol,
TG  = triglyceride and TP = total protein.
a p < 0.05.
b p < 0.01.
c p < 0.001.
Table 4
Effect of artesunate 45 days treatment on hematological parameters of rats.
Treatment  group
(mg/kg/day,  p.o)
Hb  (g/dl)  RBC  (×106/cm3)  PCV  (%)  MCV  (ﬂ)  MCH  (pg)  MCHC  (g/dl)  WBC
(×103/cm3)
NEU  (%)  LYM  (%)  MON  (%)  EOS  (%)  BAS  (%)  Platelet
(×  103/cm3)
Vehicle  control  13.90  ±  1.25  5.19  ±  0.36  51.05  ± 2.31  86.12  ±  2.16  31.97  ±  2.36  34.90  ±  2.46  43.18  ±  2.07  40.65  ±  1.63  45.13  ± 2.09  11.05  ± 1.03  2.15  ±  0.04  1.02  ±  0.02  4.17  ±  0.93
Artesunate (2)  15.62  ±  1.07ns 5.63  ±  0.79ns 46.92  ± 2.15ns 95.75  ±  3.77ns 31.15  ±  1.96ns 33.23  ±  1.66ns 44.95  ±  2.18ns 44.35  ±  2.17ns 42.35  ± 2.13ns 10.16  ± 1.20ns 2.06  ±  0.12ns 0.98  ±  0.01ns 4.42 ±  0.72ns
Artesunate (4)  11.52  ±  1.33ns 5.15  ±  0.86ns 42.85  ± 2.17ns 99.25  ±  3.15ns 32.43  ±  1.78ns 36.73  ±  2.17ns 57.63  ±  3.02b 45.09  ±  2.44ns 43.19  ± 2.33ns 7.07  ± 1.09ns 2.75  ±  0.11ns 1.90  ±  0.04c 3.5  ±  0.25ns
Artesunate (8)  10.46  ±  1.28ns 4.65  ±  0.97ns 38.15  ± 2.63b 109.23  ±  4,75b 34.16  ±  1.09ns 39.12  ±  2.05ns 59.25  ±  3.11b 50.60  ±  3.01a 36.60  ± 2.08ns 7.25  ± 1.55ns 4.45  ±  0.32c 1.10  ±  0.03ns 3.3 ±  0.36ns
n = 6. ns = not signiﬁcant when compared to vehicle control group, Hb = hemoglobin, RBC = red blood cell, PCV = packed cell volume, MCV  = mean cell volume, MCH  = mean cell hemoglobin, MCHC = mean cell
hemoglobin concentration, WBC  = white blood cell, NEU = neutrophil, LYM = lymphocyte, MON  = monocyte, EOS = eosinophil and BAS = basophil.
a p < 0.05.
b p < 0.01.
c p < 0.001.
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Fig. 4. Photomicrograph of rat liver treated with different doses of artesunate for
(2  mg/kg/day) group showing normal hepatocytes and sinusoids with mild inﬂamm
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.2. Sub-chronic toxicity of artesunate
Effect on body weight:  Body weight was determined on
ay 0, 7th, 14th, 21st, 28th, 35th and 42nd days. The body
eight of rat in control group showed gradual increase dur-
ng the 42 days treatment period up to 27.68% of weight
ain. In contrast administration of artesunate at 2, 4 and
 mg/kg/day doses showed respectively 18.35, 11.65 and
0.22% increase in body weight (Table 1).
Effect on relative weight of liver and kidney:  The intact
eight of liver and kidney was converted to relative weight
f 100 g body weight as shown in Table 2. The result showed
hat artesunate in different doses (2, 4 and 8 mg/kg/day)
dministered for 45 days has non-signiﬁcant effect on liver
nd kidney weight compared to vehicle control.
Effect on serum biochemical parameters: The effects of
rtesunate on plasma lipid levels were examined at the end
f treatment period (Table 3). Artesunate treatment for 45
ays showed signiﬁcant (p < 0.05–0.001) increase in SGOT,
GPT, ALP, TC, TG, at 4 and 8 mg/kg/day doses. Total biliru-
in level was increased only at 8 mg/kg/day dose (p < 0.05).
he level of total protein, albumin, creatinine and urea has
on-signiﬁcant effect but glucose level was elevated signif-
cant (p < 0.01) only 8 mg/kg/day dose.Effect on hematological parameters: The effect of arte-
unate on hematological indices was examined at the end
f treatment (Table 4). Treatment for 45 days has non-
igniﬁcant effect on hemoglobin, total RBC, MCH, MCHCorts 2 (2015) 280–288 285
 45 days. (A) Control group showing normal hepatocytes. (B) Artesunate
atory inﬁltration. (C) Artesunate (4 mg/kg/day) group showing sinusoidal
 diffuse focal necrosis, sinusoidal congestion, cytoplasmic vaculation and
level, differential count of lymphocytes and basophil and
total platelet count. At 8 mg/kg/day dose PCV, MCH  con-
centration was  increased signiﬁcantly (p < 0.01) along with
increase in total WBC  count, neutrophil and eosinophil per-
centage.
Histology of liver and kidney:  Light microscopic exam-
ination of liver and kidney sections of the control group
showed a normal histology of liver and kidney. Artesunate
(2 mg/kg/day) treatment showed normal hepatocytes and
sinusoids with mild inﬂammatory inﬁltration. Treatment
artesunate at 4 mg/kg/day showed sinusoidal dilation and
cytoplasmic vaculation whereas 8 mg/kg/day showed focal
necrosis, sinusoidal congestion and extensive inﬂamma-
tory changes (Fig. 4). Treatment of artesunate at all three
doses does not have any deleterious effect on histological
features of rat kidney (Fig. 5).
4. Discussion
Artesunate introduced by World Health Organization
(WHO) to combat the problems of multi-drug resistant
P. falciparum malaria [35]. Artesunate is the most widely
available artemisinin-related compounds, which is a semi-
synthetic hemisuccinate derivative of dihydroartemisinin
[36]. The artemisinin is potent antimalarial drugs that are
remarkably well tolerated [37]. Artesunate can be given
parentally, intravenously, intramuscularly, orally or rec-
tally [38].
286 P. Bigoniya et al. / Toxicology Reports 2 (2015) 280–288
tesunate
howingFig. 5. Photomicrograph of rat kidney treated with different doses of ar
artesunate (4 mg/kg/day) group and (D) artesunate (8 mg/kg/day) group s
Generally, artesunate exert its anti-malarial activity by
the generation of reactive oxygen species from its endoper-
oxide bond leading to lipid peroxidation. The reactive
oxygen species cause macromolecular damage by alkyl-
ating heme and several other proteins. The recommended
dose of artesunate is 2–10 mg/kg/day or maximum up to
200 mg/day in adult human body. Large clinical studies
with malaria patients have shown that artesunate is well
tolerated, with a few and insigniﬁcant side effects. How-
ever, several studies have showed evidence of toxicity on
the brainstem, superior colliculus, stomach, testis and liver
in artesunate treated rats. Moreover, artesunate has been
reported to destroy cancer cells and also reduces prolif-
eration, interferes in DNA replication and cell cycle and
enhance apoptosis through the intrinsic death pathway
by ROS generation. It has been reported that artesunate
is toxic to malaria parasites at nanomolar concentration,
whereas micromolar concentration is required for toxicity
in mammalian cells [39]. Evidences showed the neurotox-
icity of artesunate at high doses (50–100 mg/kg/day oral
and IM)  in laboratory animals [40] including the cytotox-
icity of artesunate on tumor cell lines have been reported
[41].
Standard sample of artesunate has been obtained as
a gift sample following which identiﬁcation and authen-
tiﬁcation was done by measurement of melting point, UV
spectroscopy, TLC and HPLC. The objective of this study
is to investigate the effect of sub-chronic oral administra-
tion of artesunate for 45 days at the dose of 2 mg/kg/day
(equivalent to half of minimum recommend therapeutic for 45 days. (A) Control group, (B) artesunate (2 mg/kg/day) group, (C)
 normal kidney histology.
dose), 4 mg/kg/day (equivalent to therapeutic dose) and
8 mg/kg/day (double the therapeutic dose) on biochemi-
cal, hematological and histological parameters of liver and
kidney. These parameters have been selected to assess the
biochemical integrity of blood cells (erythrocytes the pri-
mary site of action), liver (the site of metabolism) and
kidney (the site of excretion) due to their role in para-
siticidal action, detoxiﬁcation and eventual elimination of
artesunate in the host. The parameter assessed for hepato-
toxicity and nephrotoxicity is serum SGOT, SGPT, ALP, TG,
TC, total protein, bilirubin, albumin, creatinine, urea and
glucose level. The hematological parameters assessed were
hemoglobin, total RBC, total WBC, PCV, MCV, MCH, MCHC,
differential WBC  and platelet count along with body weight
and relative organ weight.
In the present study artesunate treatment for 45 days at
4 and 8 mg/kg/day treatment showed nearly 50% less body
weight gain in rats compared to vehicle control animals.
Artesunate showed signiﬁcant increase in SGOT, SGPT, ALP,
TC and TG at 4 and 8 mg/kg/day doses. Total bilirubin level
was  increased only at 8 mg/kg/day dose and has no effect
on total protein, albumin, creatinine and urea but glucose
level was elevated signiﬁcantly only 8 mg/kg/day dose. The
liver is the second largest organ in the body involved in
a host of functions including synthesis of clotting factors,
detoxiﬁcation and metabolism of lipids and carbohydrates.
Substantial disruption in its anatomy or function may  result
in severe alteration in its metabolic roles, and this may
adversely affect physiological functions. Release of active
oxygen species from artesunate bonded with hemoglobin
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ills the malaria parasite accumulated in the erythrocytic
ells. Artesunate may  indirectly through generation of ROS
r directly as toxin to the cells of the liver, affect their cel-
ular integrity and cause defect in membrane permeability
nd cell volume homeostasis. In humans hepatotoxicity can
e particularly severe if artesunate is used in combination
ith HIV antiretroviral drugs [42].
Izunya et al. [17] reported that artesunate treatment
t 4–8 mg/kg for 7 days has no effects on the histology
f the heart in rats. Artesunate given at 16 mg/kg, orally
or 7 days caused disturbance in liver function with dam-
ge to hepatocytes of guinea pig [16]. Hepatotoxicity and
emolytic effects of artesunate on rats at 4 mg/kg, oral
or 5 days treatment are reported by Omotuyi et al. [18].
otential hepatotoxicity of artesunate is also reported by
zunya et al. [14] at 4–8 mg/kg, orally administered for 7
ays on rats. Several studies on artesunate showed evi-
ence of toxicity on the brain stem [6,7], superior colliculus
43], stomach [44] and testis [45]. Artemisinin derivatives
howed male reproductive dysfunction and hematological
bnormalities effecting liver blood cells and testis of guinea
igs at 2–8 mg/kg oral dosing for 7 days. Nduka and Olu-
unso [15] reported alteration in biochemical parameters
f liver and kidney of rats by artesunate at 2–5 mg/kg, oral
osing for 7 days.
Artesunate has non-signiﬁcant effect on hemoglobin,
otal RBC, MCH, MCHC level, differential count of lympho-
ytes and basophil and total platelet count. Packed cell
olume and mean cell hemoglobin concentration showed
igniﬁcant rise amongst the hematological indices mea-
ured at 8 mg/kg/day dose. This may  not be connected with
rtesunate’s ability to accumulate in the red blood cells
eing the primary site of action. The RBC counts showed
tatistically insigniﬁcant difference, thus the increase in
CV may  have occurred due to decrease in plasma vol-
me  or alteration of the size and shape of the erythrocytes
46]. Since the hemoglobin concentration does not alter
n the same pattern as the PCV, the most likely alteration
ay  have occurred in the size and shape of the erythro-
ytes. This could be as a result of artesunate binding to the
lasma membrane of the erythrocytes, as it is the target site
f action. The under-lying mechanism for the parasiticidal
ctivity of artesunate is a free radical reaction [47]. This
eaction is initiated with the reaction of artesunate with
ron present in the heme prosthetic group of hemoglobin,
eading to the generation of activated oxygen species, such
s oxygen radicals and superoxide radicals. These radicals
hen propagate free radical reaction capable of inducing
xidative damage in the parasite [48]. The mechanism of
ction of these drugs and their ability to accumulate in the
ed blood cell being its primary site of action is associated
ith hemotoxicity. The hemolytic effect of artesunate at
, 4 and 8 mg/kg/day, oral for 7 days was monitored by
hanges in the packed cell volume (PCV), total bilirubin,
onjugated bilirubin and MDA  levels of erythrocyte [18].
n increased hepatocyte and erythrocyte malondialdehyde
evel was observed in 4 mg/kg/day group. The result also
howed increased activities for the serum enzymes in 2
nd 4 mg/kg/day treated groups. There is a clear indication
hat hepatotoxicity and hemotoxicity are associated with
rtesunate administration at both required and overdoseorts 2 (2015) 280–288 287
conditions however these effects are magniﬁed in overdose
conditions.
5. Conclusion
Artesunate at 4 mg/kg/day caused sinusoidal dilation
and cytoplasmic vaculation and at 8 mg/kg/day dose
showed focal diffuse necrosis, sinusoidal congestion, cyto-
plasmic vaculation and extensive inﬂammation. Rats were
orally administration with 2, 4 and 8 mg/kg/day of arte-
sunate daily for 7 days. The histological ﬁndings showed
sinusoidal congestion with cytoplasmic vaculation (hepa-
tocyte edema) and mild inﬂammation of the portal tracts
though it does not seem to induce change in relative weight
of liver. Artesunate treatment has not showed any damage
to kidney structure. This study suggests that artesunate at
normal dose has a toxic effect on the liver cells and could
be a potential hepatotoxic drug [14]. Thus, sub-chronic
exposure of artesunate at 8 mg/kg/day dose for 45 days
period may  cause hepatic damage along with hematolog-
ical abnormalities. Future studies are also required to be
done to assess the safety of this group of antimalarial drugs
in vulnerable populations, therefore, be considered in order
to generate a useful safety information and database to
improve the quality of health care offered to the patient.
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